← Leaderboards
Clayton Duncan
Valanbio Therapeutics, Inc.
$1,591,745
Attributed
$1,591,745
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $797.4K · FY2020–21$1M$750K$500K$250K$0
'20
'21
Funding mix
By agency
NIH$1,591,745 · 1
By mechanism
R44$1,591,745 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Anabolism”
- Terry Roemer · Prokaryotics, Inc.$13,565,894
- Robert Nicol · Broad Institute, Inc.$7,498,771
- Zhao Wang · Ut Southwestern Medical Center$5,368,275
- Costas Andreas Lyssiotis · University Of Michigan At Ann Arbor$4,982,483
- Yousong Ding · University Of Florida$4,468,134
- Andrew T Ulijasz · Loyola University Chicago$3,784,401
Research focus
AnabolismAnti-Bacterial AgentsAntibioticsAntimicrobial DrugBacterial CountsBactericideBasic ScienceBindingBiochemicalBiologicalBiological AvailabilityCanis FamiliarisCarbapenemaseCarbapenem ResistanceCardiovascular SystemCenters For Disease Control And Prevention (U.S.)ChromatographyClinicClinical CandidateClinical TrialsCollaborationsComplexContinuous InfusionAdverse Effects